Insilico Medicine
Generative AI platform for end-to-end drug discovery, from target identification to clinical trials
Key strengths
Insilico Medicine's Pharma.ai platform integrates multiple AI modules built on proprietary Large Language of Life Models (LLLMs) and deep generative architectures. PandaOmics performs multi-omics target discovery; Chemistry42 uses reinforcement learning and generative models to design small molecules; Generative Biologics applies similar approaches to biologics; and inClinico predicts clinical trial outcomes. The suite also includes Science42:DORA, an LLM-powered research assistant. The platform is available for licensing to pharmaceutical partners and researchers, and benchmarks are published via Insilico Bench and the Drug Discovery Benchmark to enable reproducible evaluation of AI methods.